First-Line Metastatic Pancreatic Ductal Adenocarcinoma
TOVXTheriva BiologicsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for VCN-01 (zabilugene almadenorepvec) (Oncolytic Adenovirus) in First-Line Metastatic Pancreatic Ductal Adenocarcinoma. The expected timing is based on the latest available company guidance and may change.
12/29/25:- EMA endorses VCN-01 Ph3 PDAC trial design; FDA End-of-Phase 2 meeting planned H1 2026. 03/12/26:- VIRAGE Ph2b additional analysis accepted for AACR 2026 poster. End-of-Phase 2 FDA meeting remains planned for H1 2026. 03/23/26:- Completed EOP2 FDA meeting; general agreement on planned Ph3 design; protocol finalization and funding pursued. 04/17/26:- VIRAGE Ph2b subgroup analyses presented at AACR Apr 20, 2026. FDA and EMA alignment reiterated. 05/05/26:- AACR 2026 VIRAGE subgroup data highlighted immune-mediated activity. Plan H2 2026 Spain Phase 2a dosing feasibility study. 07/07/26:- AEMPS authorized VIRAGE2 Ph2a; evaluates ≥3 VCN-01 doses with gemcitabine/nab-paclitaxel. 08/11/26:- VIRAGE2 details added; enrollment completes H2 2026; initial safety data expected Q3 2027.
Verification
Confirm timing and program details against the company announcement or filing.